Interceptor Project – Interceptor Project

focus alzheimer

The contribution of biomarkers in the early identification of prodromal form of dementia

AIM OF THE PROJECT

The goal of Interceptor is to identify among subjects with mild cognitive impairment (MCI) those with the greatest risk of evolution towards Alzheimer’s disease

THE PROJECT

SOME NUMBERS ABOUT DEMENTIA IN ITALY

600.000: patiens affected by Alzheimer’s disease

1.200.000: patients with dementia

3.000.000: people directly or indirectly involved in care giving

6.000.000.000: the total amount of costs attributable to Alzheimer’s disease

Alzheimer’s represents about 50% of total dementia diseases

ARE YOU ELIGIBLE?

Subjects that will meet the criteria for MCI according to the National Institute on Aging-Alzheimer’s Association work groups on Diagnostic Guidelines for Alzheimer’s Disease (Albert et al., 2011)will be enrolled in to the study
ELIGIBLE SUBJECTS WILL BE INVITED BY THE CLOSEST RECRUITING CENTER DURING THE PERIOD BETWEEN JANUARY AND JULY 2019.

FIND OUT MORE

RATIONAL OF THE PROJECT

INTERCEPTOR focuses on the diagnosis of the “prodromal” stage of Alzheimer’s disease, when symptoms are still absent or very blurred in order to start a pharmacological intervention at earliest to slow down the disease progression.

PROJECT’S PARTNERS

Interceptor is coordinated by “Agostino Gemelli” Polyclinic Foundation in Rome and sponsored by AIFA and the Ministry of Health.
.

THE PARTNERS